| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Cholesteryl palmitate primarily targets proteins such as JAK2 and PIK3CA, which are involved in signal transduction and cell proliferation. The compound interacts with these targets through molecular docking, influencing cellular processes they regulate. This interaction can influence the PI3K-Akt signaling pathway, which plays a crucial role in cell survival and growth. The compound is involved in the cholesterol metabolism pathway, and its action can influence the expression of genes such as JAK2, PPARG, PI3K, and AKT1.
|
|---|---|
| ln Vitro |
In vitro, Cholesteryl palmitate is utilized to study lipid behavior, membrane composition, and the role of lipids in cell signaling. It has been employed in research to create stable tear films for the investigation of amphiphilic block copolymers as surfactants. The compound's interactions with JAK2 and PIK3CA have been characterized through molecular docking studies. Its role as an endogenous metabolite allows for the study of cholesterol ester function in various biological processes.
|
| ln Vivo |
In vivo, Cholesteryl palmitate serves as a prognostic biomarker for chronic interstitial pneumonia and as a predictor of fetal lung maturity. The compound is a major component of human meibum and has been used to form stable tear films for dry eye research. As an endogenous metabolite, it is involved in cholesterol metabolism and lipid transport. Its levels in biological fluids can reflect lipid metabolism status and are associated with inflammatory responses in arterial walls.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Cholesteryl palmitate typically involve studying its interactions with target proteins such as JAK2 and PIK3CA using molecular docking techniques. These assays assess binding affinity and the resulting changes in target protein activity. For lipid metabolism studies, the compound is used to investigate the activity of enzymes involved in cholesterol ester hydrolysis and synthesis. Membrane fluidity and lipid bilayer studies may employ Cholesteryl palmitate as a model cholesterol ester to assess its effects on membrane properties. Assays are performed in appropriate buffer systems with positive controls.
|
| Cell Assay |
In vitro cell-based assays for Cholesteryl palmitate are conducted in various cell lines to study lipid metabolism and cell signaling. Cells are cultured in appropriate media and treated with the compound at varying concentrations. The effects of Cholesteryl palmitate on gene expression of JAK2, PPARG, PI3K, and AKT1 are assessed by qPCR or Western blot. Lipid accumulation and metabolism are evaluated by measuring cellular cholesterol ester content. Cell viability is assessed by standard assays such as MTT. Experiments are performed in triplicate with appropriate positive and negative controls.
|
| Animal Protocol |
In vivo animal studies for Cholesteryl palmitate are conducted in models of lipid metabolism and inflammatory diseases. Animals are administered the compound via diet or injection. For biomarker studies, blood and tissue samples are collected to measure Cholesteryl palmitate levels and assess its correlation with disease progression. For tear film studies, animal models of dry eye are used to evaluate the compound's effectiveness in forming stable tear films. Animals are monitored for clinical signs, and tissues are collected for histopathological and biochemical analysis at study endpoints. Studies are conducted in accordance with institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
Cholesteryl palmitate (MW 625.1 g/mol, C43H76O2) is a lipophilic cholesterol ester. It is a white, waxy solid naturally found in the human body and various food products. The compound is soluble in chloroform and other organic solvents. It is stable under recommended storage conditions. Pharmacokinetic parameters such as absorption, distribution, metabolism, and excretion are consistent with other cholesterol esters, involving incorporation into lipoproteins and hepatic metabolism. The compound is used in the cosmetic and pharmaceutical industries.
|
| Toxicity/Toxicokinetics |
Cholesteryl palmitate is generally considered safe as an endogenous metabolite and food component. It is a major cholesterol ester found in human plasma, constituting about two-thirds of plasma cholesterol. The compound is involved in chronic inflammatory responses in arterial walls, largely due to lipoprotein deposition. No significant adverse effects have been reported at research-use concentrations. The compound is intended for research use only. Standard safety precautions should be followed when handling. Comprehensive toxicological evaluation is available from nutritional and lipid metabolism studies.
|
| References | |
| Additional Infomation |
Cholesterol palmitate is a cholesterol ester formed by the condensation of cholesterol and palmitic acid. It is a metabolite in both humans and mice. Its function is related to hexadecanoic acid. There are reports and data regarding the presence of cholesterol palmitate in Homo sapiens.
Cholesteryl palmitate (Cholesterol palmitate) is a cholesterol ester formed by the esterification of cholesterol with palmitic acid, playing a significant role in lipid storage, transport, and membrane composition. It is a major cholesterol ester in human meibum and plasma, serving as a prognostic biomarker for chronic interstitial pneumonia and a predictor of fetal lung maturity. The compound targets JAK2 and PIK3CA, influencing the PI3K-Akt signaling pathway. It is utilized in research to study lipid metabolism, membrane fluidity, and cell signaling. All applications are limited to non-human research use. |
| Molecular Formula |
C43H76O2
|
|---|---|
| Molecular Weight |
625.0624
|
| Exact Mass |
624.584
|
| CAS # |
601-34-3
|
| Related CAS # |
Cholesteryl palmitate-d9;Cholesteryl palmitate-d7;1416275-32-5
|
| PubChem CID |
246520
|
| Appearance |
White to off-white solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
651.5±34.0 °C at 760 mmHg
|
| Melting Point |
74-77 °C(lit.)
|
| Flash Point |
347.8±13.2 °C
|
| Vapour Pressure |
0.0±2.0 mmHg at 25°C
|
| Index of Refraction |
1.506
|
| LogP |
18.14
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
21
|
| Heavy Atom Count |
45
|
| Complexity |
904
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
CCCCCCCCCCCCCCCC(=O)O[C@H]1CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3CC=C2C1)CC[C@@H]4[C@H](C)CCCC(C)C)C)C
|
| InChi Key |
BBJQPKLGPMQWBU-JADYGXMDSA-N
|
| InChi Code |
InChI=1S/C43H76O2/c1-7-8-9-10-11-12-13-14-15-16-17-18-19-23-41(44)45-36-28-30-42(5)35(32-36)24-25-37-39-27-26-38(34(4)22-20-21-33(2)3)43(39,6)31-29-40(37)42/h24,33-34,36-40H,7-23,25-32H2,1-6H3/t34-,36+,37+,38-,39+,40+,42+,43-/m1/s1
|
| Chemical Name |
[(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] hexadecanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
THF :≥ 100 mg/mL (~159.98 mM)
H2O : < 0.1 mg/mL Ethanol :< 1 mg/mL DMSO :< 1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5998 mL | 7.9992 mL | 15.9985 mL | |
| 5 mM | 0.3200 mL | 1.5998 mL | 3.1997 mL | |
| 10 mM | 0.1600 mL | 0.7999 mL | 1.5998 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
